Pacritinib and Fedratinib, both JAK2-selective inhibitors that display efficacy in myeloproliferative disorders, are being investigated for their relevance in solid tumors like BC and have shown promising results in reducing STAT3 activity and tumor progression in TNBC models. This evidence concerns the gene STAT3 and breast cancer.